Cholecystokinin peptides, dopamine and schizophrenia--a review.
CCK-IR is co-localized with DA in some DA neurons projecting to limbic structures. The extent of the co-localization is species dependent. The co-localization of CCK and DA is of interest in view of the DA hypothesis of schizophrenia and the putative role of limbic dysfunction in the pathophysiology of this disorder. In animals biochemical, electrophysiological and behavioural studies point to an interaction between CCK and DA. Whereas some investigations point to an inhibitory effect on DA function, which would be compatible with a potential antischizophrenic action, others point to an enhancement or no effect. CCK peptides show a neuroleptic-like profile in several screening tests for neuroleptics but not in all studies. In man there is endocrinological evidence for an inhibitory effect of CCK-33 and CCK-8 on DA function. However, alternate explanations are possible. CSF CCK-IR is unchanged or decreased in schizophrenia. Autopsy investigations have shown significant decreases, increases or no change in brain CCK-IR concentrations and a decrease in CCK-33 binding in schizophrenia. Eight of 11 clinical trials with CER, CCK-8 or CCK-33 have shown a therapeutic effect in schizophrenia; only two of these eight trials have been double-blind studies. The three controlled investigations which have shown no effect have used only small patient populations. None of the trials have used an active placebo. It is difficult to reconcile the apparent long duration of antipsychotic activity with the short half-life of the peptides and problems of the peptides in crossing the blood brain barrier. Despite these apparent anomalies information to date is sufficiently impressive to warrant further detailed investigation of CCK-DA-interactions and the evaluation of the clinical effects of a variety of CCK peptides and related compounds, natural and synthetic, which may more easily cross the blood brain barrier and which may show regional selectivity in site of action in brain.
Nair
N P
NP
Lal
S
S
Bloom
D M
DM
D014150:Antipsychotic Agents / Q000494:pharmacology; D002108:Ceruletide / Q000627:therapeutic use; D002766:Cholecystokinin / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D006801:Humans; D018377:Neurotransmitter Agents / Q000134:cerebrospinal fluid / Q000378:metabolism; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism; D012559:Schizophrenia / Q000378:metabolism*; D012844:Sincalide / Q000627:therapeutic use
D014150:Antipsychotic Agents; D018377:Neurotransmitter Agents; D011954:Receptors, Dopamine; D002108:Ceruletide; D002766:Cholecystokinin; D012844:Sincalide; D004298:Dopamine